With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company’s goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months.

“We are now ready to start making Pepaxti accessible to patients who urgently need new and innovative treatment options, and we expect to commence launch activities during the first quarter,” said Bruno Bolognese, Country Manager Italy and European Head of Medical Affairs at Oncopeptides. “Italy represents a key market for Oncopeptides, with its large patient population and extensive clinical experience with Pepaxti.”

Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti’s target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement.

As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.

For more information, please visit www.oncopeptides.com